ADVFN - Advanced Financial Network.
HOME» NASDAQ » A » ARNA Stock Price » ARNA Stock News

Arena Share News

 Arena Pharmaceuticals (mm) Stock Price
ARNA Stock Price
 Arena Pharmaceuticals (mm) Stock Chart
ARNA Stock Chart
 Arena Pharmaceuticals (mm) Stock News
ARNA Stock News
 Arena Pharmaceuticals (mm) Company Information
ARNA Company Information
 Arena Pharmaceuticals (mm) Stock Trades
ARNA Stock Trades

Approvals Of New Drugs Down In 2010 Vs 2009, 2008

By Jennifer Corbett Dooren Of DOW JONES NEWSWIRES WASHINGTON -(Dow Jones)- The number of new drugs approved by the Food and Drug Administration in 2010 looks to be about 21, a relatively low figure that shows the pharmaceutical industry hasn't yet escaped its drought in recent years. A few potential blockbusters won approval during the year, but others got delayed partly reflecting a tougher regulatory environment amid ongoing concerns about drug safety. According to monthly drug-approval reports generated on FDA's website, 21 new types of drugs were approved in 2010, down from 25 in 2009 and 24 in 2008, but higher from a recent low of 18 in 2007. Final approval figures as well as the number of applications received by the agency in 2010 won't be available until next month. Although the 2010 figures are a bit lower than previous years, the FDA said there's "no systemic change in how the FDA is approaching drug approvals." Sandy Walsh, an agency spokeswoman, noted that drug applications come in on a rolling basis making it difficult to compare one calendar year to another. She said the primary factor driving approvals "is the quality of the application and the quality of the data that support the drug's safety and efficacy." Amgen Inc. (AMGN) won approval for Prolia, a drug that is injected twice yearly to treat osteoporosis in postmenopausal women while Roche Holding Ltd.'s (RHHBY) biotech unit, Genentech, won approval for Actemra, a drug that is administered intravenously to treat rheumatoid arthritis. Boehringer Ingelheim GmbH received approval for a new type of blood-thinning drug, Pradaxa, to prevent strokes in patients with irregular heart rhythms, potentially replacing much warfarin use, an old, widely-used anticoagulant approved in 1954. Patients with multiple sclerosis saw advances in treatment with the October approval of Novartis AG's (NVS) Gilenya, an oral product. Multiple sclerosis has traditionally been treated by injections or infusions. Earlier in the year, FDA also approved Acorda Therapeutics Inc.'s (ACOR) drug, Ampyra, to improve walking in MS patients. In August, the FDA approved ella, a longer lasting emergency contraceptive that is designed to block pregnancy up to five days after sex. The product was developed by HRA Pharma, a closely-held company in Paris, and was launched in the U.S. earlier this month by Watson Pharmaceuticals Inc. (WPI). In April Dendreon Corp. (DNDN) won approval for its prostate cancer therapy Provenge, which had previously been rejected by the agency. Provenge is designed to use a patient's own cells to stimulate the body's immune system to fight the cancer and may be the first in a new class of cancer-fighting drugs. However, 2010 may be more notable for drugs that weren't approved as well as for drugs the agency restricted or pulled off the market. The FDA refused to approve AstraZeneca PLC's (AZN) blood-thinning drug Brilinta and asked the company earlier this month for more information about one of the studies submitted in support of the product's approval. The also rejected a long-acting version of diabetes drug Byetta, sold by Amylin Pharmaceuticals Inc. (AMLN) and Eli Lilly & Co. (LLY), saying more clinical data is needed to address cardiovascular safety concerns. In October the FDA declined to approve two proposed weight-loss drugs from Arena Pharmaceuticals Inc. (ARNA) and Vivus Inc. (VVUS). The FDA closed the books on one of the highest profile drug-safety matters in recent years by sharply curtailing the use of GlaxoSmithKline PLC's (GSK) diabetes drug Avandia in September after it was linked an increased risks of heart attacks. In October the agency removed Abbott Laboratories (ABT) weight-loss drug Meridia from the market, saying the drug didn't work well enough to justify potential heart problems. A month later the makers of decades-old painkillers Darvon and Darvocet agreed to take those drugs off the market on concerns about an increased risk of serious abnormal heart rhythms. In December, the FDA said it would move to revoke the approval of Roche's cancer drug Avastin for use in breast cancer saying the product didn't appear to help patients live longer. The decision won't affect use of Avastin in other types of cancers. The agency also delayed some decisions in 2010, saying this week it needed more time to review MannKind Corp.'s (MNKD) inhaled-insulin product to treat diabetes. It also said it needed until next March to review Benlysta, a highly anticipated lupus drug from Human Genome Sciences Inc. (HGSI) and GlaxoSmithKline. --By Jennifer Corbett Dooren, Dow Jones Newswires; 202-862-9294; jennifer.corbett@dowjones.com.

Stock News for Arena (ARNA)
DateTimeHeadline
11/15/201309:18:03OZ Management LP 3Q 13F: Largest Purchases -2-
11/15/201309:18:02OZ Management LP 3Q 13F: Largest Purchases
11/15/201308:27:55S.A.C. Capital Advisors LP 3Q 13F: Largest Eliminations
11/15/201308:27:52S.A.C. Capital Advisors LP 3Q 13F: Largest -2-
11/15/201308:27:52S.A.C. Capital Advisors LP 3Q 13F: Largest Sales
11/15/201308:27:52S.A.C. Capital Advisors LP 3Q 13F: Largest Purchases
01/17/201309:20:44U.S. HOT STOCK FUTURES: HOT STOCKS TO WATCH
01/07/201311:14:02Vivus's Free Promotion Lifts Prescriptions for Diet Drug
12/05/201215:02:25FDA Approves Highest Number of New Drugs Since 2004
07/19/201217:15:53Vivus Shares Drop Amid Report Questioning Diet Drug's Prospects
05/11/201217:25:10Dow Drops After JP Morgan Trading Loss; Consumer Sentiment Rises
03/26/201217:00:06US Stocks Erase Last Week's Losses; S&P Ends With Nearly Four-Year...
03/26/201209:12:54US STOCK FUTURES: HOT STOCKS TO WATCH
01/11/201209:09:45US Stock Futures: HOT STOCKS TO WATCH
01/10/201209:03:04Arena: FDA Accepts Resubmitted Application For Weight-Loss Drug...
11/22/201111:14:30Registration Effectiveness Orders Issued By The SEC
08/02/201107:29:39Arena, Eisai Diet Drug Less Concentrated In Human Brain Than...
02/17/201109:07:03Orexigen Financial Chief Cooper Resigns
02/10/201117:54:48Arena Pharma Finance Chief Hoffman To Leave Company
02/01/201116:14:46Diet Drug Decision Shows Why Drug Makers Have Kept Distance

Arena Pharmaceuticals and other NASDAQ stock quotes are delayed by at least 20 minutes.
All other stock price and quote data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad